Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Srdan Verstovsek

Showing results (1-10 of 644) with videos related to

Pageof 65
Sort By:
Leukemia & Lymphoma|July 9, 2013
Tips on using ruxolitinib in everyday practice as therapy for myelofibrosisSrdan Verstovsek
Clinical Advances in Hematology & Oncology : H&O|December 9, 2016
Highlights in polycythemia vera from the 2016 EHA congressSrdan Verstovsek
Blood|March 22, 2014
Changing myelofibrosis's natural course at lastSrdan Verstovsek
Postgraduate Medicine|February 9, 2013
Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosisSrdan Verstovsek
Oncology (Williston Park, N.Y.)|August 28, 2013
Ruxolitinib for myelofibrosis: from 'palliation' to prolongation of survivalSrdan Verstovsek
Hematology. American Society of Hematology. Education Program|December 17, 2009
Therapeutic potential of JAK2 inhibitorsSrdan Verstovsek
Clinical Advances in Hematology & Oncology : H&O|February 12, 2009
JAK2 inhibitors and myeloproliferative neoplasmsSrdan Verstovsek
Best Practice & Research. Clinical Haematology|September 6, 2014
PrefaceSrdan Verstovsek
Clinical Advances in Hematology & Oncology : H&O|March 10, 2012
Ruxolitinib: the first agent approved for myelofibrosisSrdan Verstovsek
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
New therapies for polycythemia veraSrdan Verstovsek
Pageof 65

Showing results (1-10 of 644) with videos related to

Sort By:
Pageof 65
Leukemia & Lymphoma|July 9, 2013
Tips on using ruxolitinib in everyday practice as therapy for myelofibrosisSrdan Verstovsek
Clinical Advances in Hematology & Oncology : H&O|December 9, 2016
Highlights in polycythemia vera from the 2016 EHA congressSrdan Verstovsek
Blood|March 22, 2014
Changing myelofibrosis's natural course at lastSrdan Verstovsek
Postgraduate Medicine|February 9, 2013
Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosisSrdan Verstovsek
Oncology (Williston Park, N.Y.)|August 28, 2013
Ruxolitinib for myelofibrosis: from 'palliation' to prolongation of survivalSrdan Verstovsek
Hematology. American Society of Hematology. Education Program|December 17, 2009
Therapeutic potential of JAK2 inhibitorsSrdan Verstovsek
Clinical Advances in Hematology & Oncology : H&O|February 12, 2009
JAK2 inhibitors and myeloproliferative neoplasmsSrdan Verstovsek
Best Practice & Research. Clinical Haematology|September 6, 2014
PrefaceSrdan Verstovsek
Clinical Advances in Hematology & Oncology : H&O|March 10, 2012
Ruxolitinib: the first agent approved for myelofibrosisSrdan Verstovsek
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
New therapies for polycythemia veraSrdan Verstovsek
Pageof 65